The Use of Near-Infrared Light-Emitting Fluorescent Nanodiamond Particles to Detect Ebola Virus Glycoprotein: Technology Development and Proof of Principle
Giora Z Feuerstein,Michael A Mansfield,Peter I Lelkes,Salvatore Alesci,Cezary Marcinkiewicz,Nathan Butlin,Mark Sternberg
DOI: https://doi.org/10.2147/IJN.S261952
IF: 7.033
2020-10-08
International Journal of Nanomedicine
Abstract:Giora Z Feuerstein, 1 Michael A Mansfield, 2 Peter I Lelkes, 3 Salvatore Alesci, 1 Cezary Marcinkiewicz, 1, 3 Nathan Butlin, 4 Mark Sternberg 1 1 Debina Diagnostics Inc., Newtown Square, PA, USA; 2 MilliporeSigma, Bedford, MA, USA; 3 Department of Bioengineering, Temple University, Philadelphia, PA, USA; 4 Axxin Pty Ltd, Fairfield, VIC, Australia Correspondence: Giora Z Feuerstein Debina Diagnostics Inc., Newtown Square, PA, USA Tel +1 4842221575 Email cmarcik@temple.edu Background: There is a dire need for rapid diagnostic tests of high sensitivity, efficiency, and point-of-test reporting capability to mitigate lethal viral epidemic outbreaks. Purpose: To develop a new operating system within the lateral flow assay (LFA) format for Ebola virus (EBOV), based on fluorescent nanodiamond particles (FNDP) nitrogen vacancy (NV) emitting near-infrared (NIR) light. Specifically, we aimed to detail technical issues and the feasibility of mobilizing FNDP-NV on nitrocellulose membranes (NCM) and capturing them at test and control lines. Methods: FNDP-NV-200nm, 400nm or 800nm were linked to anti-EBOV glycoprotein (GP) monoclonal antibodies (mAb) and tested for LFA performance by monitoring NIR emissions using an in vivo imaging system or optoelectronic device (OED). Anti-EBOV recombinant glycoprotein (GP) humanized mAb c13C6 was linked to FNDP-NV-200nm for the mobile phase; and a second anti-GP mouse mAb, 6D8, was printed on NCM at the test line. Goat anti-human IgG (GAH-IgG) served as a nonspecific antibody for conjugated FNDP-NV-200nm at the control line. Results: FNDP-NV-200nm-c13C6 specifically and dose-dependently bound to recombinant EBOV GP in vitro and was effectively captured in a sandwich configuration at the test line by mAb 6D8. FNDP-NV-200nm-c13C6 was captured on the control line by GAH-IgG. The OED quantitative analysis of NIR (obtained in less than 1 minute) was further validated by an in vivo imaging system. Conclusion: FNDP-NV-200nm performance as a reporter for EBOV GP rapid diagnostic tests suggests an opportunity to replace contemporary visual tests for EBOV GP and other highly lethal viral pathogens. Mobile, battery-operated OED adds portability, quantitative data, rapid data collection, and point-of-test reporting capability. Further development of FNDP-NV-200nm within a LFA format is justified. Keywords: Ebola virus, diagnostic lateral flow test, LFA, opto-electronic reader, OER, anti-EBOV antibodies, nitrocellulose membranes, fluidics technology
pharmacology & pharmacy,nanoscience & nanotechnology